By: Mamta Mayani, SA News Editor From: seekingalpha.com Oncolytics Biotech (NASDAQ:ONCY) doses first patient in its phase 2 study of pelareorep-based combination therapies in HR+/HER2- metastatic breast cancer (mBC). The study, known as BRACELET-1, is being conducted under a co-development agreement with Merck KGaA (OTCPK:MKGAY) and Pfizer (NYSE:PFE). Participants will receive paclitaxel, pelareorep in combination with paclitaxel alone, or pelareorep in combination with …
Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer
From: biospace.com AWARE-1 trial demonstrates pelareorep primes an adaptive immune response Systemic delivery yields robust pelareorep replication selectively in tumor cells Pelareorep administration increases CelTIL – known to be associated with positive clinical outcomes Peripheral T cell clonality emerges as potential predictive and prognostic biomarker Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, …